{
    "clinical_study": {
        "@rank": "53859", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV\n      vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV\n      injected into the muscle to the effects of the drug when injected into the skin."
        }, 
        "brief_title": "A Study of GENEVAX-HIV, a Possible Vaccine", 
        "condition": [
            "HIV Infections", 
            "HIV Seronegativity"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Volunteers receive either intradermal or intramuscular injections of GENEVAX-HIV; humoral\n      and cellular responses are assessed accordingly."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Good health.\n\n          -  Ability to understand the basis of HIV transmission and other common sexual and\n             blood-borne infections.\n\n          -  The following parameters within normal range:\n\n          -  Hematopoietic:\n\n          -  total white blood cell, lymphocyte, granulocyte, and platelet count, hemoglobin and\n             hematocrit.\n\n          -  Renal:\n\n          -  BUN and creatinine, urinalysis.\n\n          -  Hepatic:\n\n          -  total serum bilirubin.\n\n          -  Endocrine/Metabolic:\n\n          -  Serum calcium, serum glucose, total serum CPK.\n\n          -  Immunologic:\n\n          -  total serum immunoglobulin and absolute CD4 count.\n\n          -  Hepatitis B and Hepatitis C negative.\n\n          -  Urinalysis:\n\n          -  Normal screen with dipstick for esterase and nitrite.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  HIV-seropositive status.\n\n          -  Any positive result for anti-DNA antibodies considered of potential clinical\n             significance as measured by anti-DNA antibody and/or anti-nuclear antibody (ANA)\n             assays.\n\n          -  Any condition which, in the opinion of the principal investigator, might interfere\n             with completion of the study or evaluation of the results.\n\n          -  Known hypersensitivity to bupivacaine or any amide-type local anesthetic (such as\n             lidocaine, dibucaine, mepivacaine, and prilocaine) or a history of anaphylaxis or\n             other serious adverse reactions to vaccines.\n\n        Concurrent Medication:\n\n        Excluded:\n\n        Any medication which may affect immune function with the exception of low doses of\n        nonprescription-strength NSAIDS, aspirin, or acetaminophen for acute conditions such as\n        headache or trauma.\n\n        Patients with the following prior conditions are excluded:\n\n          -  HIV-seropositive.\n\n          -  Known or suspected history of impairment or abnormality in immune functioning.\n\n          -  Exposure to potentially-infective HIV fluids within the prior 6 months or tested\n             positive for HIV at any time.\n\n          -  History of any prior disease or therapy which would affect immune function including:\n\n          -  Prior malignancy, except curatively-treated basal cell or squamous cell carcinoma in\n             situ of the cervix.\n\n          -  Immunodeficiency or autoimmune disease.\n\n          -  Acute infection or a recent (within 6 months) history of chronic infection.\n\n          -  History of serious allergic reaction to any substance requiring hospitalization or\n             emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension).\n\n        Prior Medication:\n\n        Excluded:\n\n        Cytotoxic chemotherapy that may affect immune function.\n\n        Prior Treatment:\n\n        Excluded:\n\n          -  Previous immunization with any experimental vaccines directed against HIV or receipt\n             of any experimental agent within 30 days prior to enrollment.\n\n          -  Receipt of any blood products or immunoglobulin within 6 months prior to enrollment.\n\n          -  Exposure to live attenuated vaccines within 60 days of study.\n\n          -  Radiotherapy that may affect immune function.\n\n        Risk Behavior:\n\n        Excluded:\n\n          -  Active drug or alcohol abuse or uncontrolled (unstable) psychiatric disorders which,\n             in the opinion of the investigator, would interfere with study participation.\n\n          -  Higher- or intermediate-risk sexual behavior (AVEG criteria)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002232", 
            "org_study_id": "005", 
            "secondary_id": "400-003-05"
        }, 
        "intervention": {
            "intervention_name": "APL 400-003", 
            "intervention_type": "Biological"
        }, 
        "keyword": [
            "Injections, Intradermal", 
            "Injections, Intramuscular", 
            "HIV Antibodies", 
            "Immunity, Cellular", 
            "AIDS Vaccines", 
            "HIV Seronegativity", 
            "Dose-Response Relationship, Immunologic", 
            "Vaccines, DNA", 
            "Immunity, Mucosal"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20307"
                }, 
                "name": "Walter Reed Army Institute of Research"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "GENEVAX-HIV (APL 400-003), a Candidate DNA Vaccine: A Pilot Study of GENEVAX-HIV Given by Intramuscular or Intradermal Administration in HIV Seronegative Volunteers", 
        "overall_official": {
            "last_name": "Merlin Robb", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002232"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Wyeth-Lederle Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "June 1999"
    }, 
    "geocoordinates": {
        "Walter Reed Army Institute of Research": "38.895 -77.036"
    }
}